|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Identification of osteopontin as the most consistently over-expressed gene in intrahepatic cholangiocarcinoma: Detection by oligonucleotide microarray and real-time PCR analysis显示文摘AIM: To investigate the molecular pathways involved in human cholangiocarcinogenesis by gene expression profiling. METHODS: Oligonucleotide arrays (Affymetrix U133A) were used to establish a specific gene expression profile of intrahepatic CCC in comparison to corresponding non- malignant liver tissue. To validate the expression values of the most overexpressed genes, RT-PCR experiments were performed. RESULTS: Five hundred and fifty-two statistically differentially expressed genes/ESTs (221 probes significantly up-regulated, 331 probes down-regulated; P < 0.05; fold change > 2; ≥ 70%) were identified. Using these data and two-dimensional cluster analysis,a specific gene expression profile was obtained allowing fast and reproducible differentiation of CCC, which was confirmed by supervised neuronal network modelling. The most consistently overexpressed gene (median fold change 33.5, significantly overexpressed in 100%) encoded osteopontin. Furthermore, an association of various genes with the histopathological grading could be demonstrated. CONCLUSION: A highly specific gene expression profile for intrahepatic CCC was identified, allowing for its fast and reproducible discrimination against non- malignant liver tissue and other liver masses. The most overexpressed gene in intrahepatic CCC was the gene encoding osteopontin. These data may lead to a better understanding of human cholangiocarcinogenesis. | Holger G Hass Oliver Nehls Juergen Jobst Andrea Frilling Ulrich Vogel Stephan Kaiser | 2008 | World Journal of Gastroenterology2008，14，16： | 4 |
| 2 | Lycopene as the most efficient biological caratenoid single oxygen quencher显示文摘 | Di Mascio Stephan Kaiser Helmur Sies | 1989 | Archives of Biochemistry and Biophysics1989，274，2： | 1 |
| 3 | Lycopene as the most efficient biological carotenoid singlet oxygen quencher 显示文摘 | Paolo Di Mascio Stephan Kaiser and Helmut Sies | 1989 | Archives of Biochemistry and Biophysics1989，274，2： | 1 |
| 4 | Lycopene as the most efficient biological carotenoid singlet oxygen quencher显示文摘 | Paolo Di Mascio Stephan Kaiser Helmur Sies | 1989 | Archives of Biochemistry and Biophysics1989，274，2： | 1 |
| 5 | The 1.5GeV harmonic double-sided microtron at Mainz University显示文摘 | K.-H. Kaiser K. Aulenbacher O. Chubarov M. Dehn H. Euteneuer F. Hagenbuck R. Herr A. Jankowiak P. Jennewein H.-J. Kreidel U. Ludwig-Mertin M. Negrazus S. Ratschow St. Schumann M. Seidl G. Stephan A. Thomas | 2008 | Nuclear Inst. and Methods in Physics Research, A2008，，3： | 1 |
| 6 | Dis- posable bioreactors: the current state-of-the-art and recom- mended applications in biotechnology 显示文摘 | Regine Eibl Stephan Kaiser Renate Lombriser | 2010 | Applied Microbi- ology and Biotechnology2010，86，3： | 1 |
| 7 | Lycopene as the most efficient biological caratenoid singlet oxygen quencher 显示文摘 | Di Mascio Paolo Kaiser Stephan Sies Helmut | 1989 | Archives of Biochemistryand Biophysics1989，274，2： | 1 |
| 8 | Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary revascularisation (BIOSCIENCE): a randomised, single-blind, non-inferiority trial显示文摘 | Thomas Pilgrim Dik Heg Marco Roffi David Tüller Olivier Muller André Vuilliomenet Stéphane Cook Daniel Weilenmann Christoph Kaiser Peiman Jamshidi Therese Fahrni Aris Moschovitis Stéphane Noble Franz R Eberli Peter Wenaweser Peter Jüni Stephan Windecker | 2014 | 2014 (9960)2014，，9960： | 1 |
| 9 | High-dose interferon-α2b induction therapy in combination with ribavirin for treatment of chronic hepatitis C in patients with non-response or relapse after interferon-a monotherapy显示文摘AIM: To evaluate the daily high-dose induction therapy with interferon-α2b (IFN-α2b) in combination with ribavirin for the treatment of patients who failed with interferon monotherapy and had a relapse, based on the assumption that the viral burden would decline faster, thus increasing the likelihood of higher response rates in this diffficult-to-treat patient group.METHODS: Seventy patients were enrolled in this study.Treatment was started with 10 MU IFN-α2b daily for 3 wk,followed by IFN-α2b 5 MU/TIW in combination with ribavirin (1 000-1 200 mg/d) for 21 wk. In case of a negative HCV RNA PCR, treatment was continued until wk 48 (IFN-α2b 3 MU/TIW+1 000-1 200 mg ribavirin/daily).RESULTS: The dose of IFN-α2b or ribavirin was reduced in 16% of patients because of hematologic side effects,and treatment was discontinued in 7% of patients. An early viral response (EVR) was achieved in 60% of patients. Fifty percent of all patients achieved an end-of-treatment response (EOT) and 40% obtained a sustained viral response (SVR). Patients with no response had a significantly lower response rate than those with a former relapse (SVR 30% vs 53%; P = 0.049). Furthermore,lower response rates were observed in patients infected with genotype 1a/b than in patients with non-1-genotype (SVR 28% vs74%; P= 0.001). As a significant predictive factor for a sustained response, a rapid initial decline of HCV RNA could be identified. No patient achieving a negative HCV-RNA PCR at wk 18 or later eventually eliminated the virus.CONCLUSION: Daily high-dose induction therapy with interferon-α2b is well tolerated and effective for the treatment of non-responders and relapsers, when interferon monotherapy fails. A fast decline of viral load during the first 12 wk is strongly associated with a sustained viral response. | Holger G. Hass Christian Kreysel Johannes Fischinger Josef Menzel Stephan Kaiser | 2005 | World Journal of Gastroenterology2005，11，34： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员